Parte del contenido de esta aplicación no está disponible en este momento.
Si esta situación persiste, contáctenos aComentarios y contacto
1. (WO1999046988) COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC VACCINATION
Nota: Texto obtenido mediante procedimiento automático de reconocimiento óptico de caracteres.
Solo tiene valor jurídico la versión en formato PDF

CLAIMS

1. A method of inducing a prophylactic immune response to a self-antigen in a subject, comprising administering to the subject an effective amount of the antigen or an altered form of the antigen.

2. The method of claim 1 , wherein the antigen is administered as a polynucleotide coding for the self-antigen.

3. The method of claim 2, wherein the polynucleotide is delivered as naked DNA.

4. The method of claim 2, wherein the polynucleotide is delivered in a gene delivery vehicle.

5. The method of claim 1, further comprising administering an effective amount of an immunostimulatory agent to the subject.

6. The method of claim 5, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

7. The method of claim 1 , wherein the antigen is administered in an antigen presenting cell.

8. The method of claim 7, wherein the antigen presenting cell has been genetically modified by insertion of a polynucleotide coding for the antigen.

9. The method of claim 7, wherein the antigen presenting cell is a foster antigen presenting cell, a hybrid antigen presenting cell, or a pulsed antigen presenting cell.

10. The method of claim 7, wherein the antigen presenting cell is a dendritic cell.

11. The method of claim 7, further comprising administering an effective amount of an immunostimulatory agent to the subject.

12. The method of claim 11 , wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

13. The method of claim 1 or 7, wherein the self-antigen is a tumor associated antigen (TAA).

14. A method of providing a prophylactic immune response to a self-antigen in a subject, comprising administering to the subject an effective amount of educated immune effector cells, educated to specifically recognize and lyse cells expressing the self-antigen or an altered form of the self-antigen.

15. The method of claim 14, wherein the immune effector cells have been produced by stimulating naϊve immune effector cells with antigen presenting cells that present the antigen or an altered self-antigen to the naϊve immune effector cells.

16. The method of claim 14, wherein the educated immune effector cells are produced ex vivo.

17. The method of claim 14, wherein the educated immune effector cells are produced in vivo.

18. The method of claim 14, further comprising administering an effective amount of an immunostimulatory agent.

19. The method of claim 18, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

20. The method of claim 1 or 14, wherein the subject is characterized as being in a disease-free state but genetically predisposed to a condition subject to immune surveillance.

21. The method of claim 20, wherein the condition is associated with the presence of the HER-2/neu gene in the subject.

22. The method of claim 1 or 14, wherein the subject is characterized as being in a disease free interval of a condition subject to immune surveillance.

23. The method of claim 22, wherein the condition is melanoma.